Research programme: musculoskeletal therapeutics - Arcarios
Alternative Names: ARC-118; ARC-205; BMP modulators - ArcariosLatest Information Update: 03 Aug 2018
At a glance
- Originator TiGenix
- Developer Arcarios
- Class Recombinant fusion proteins; Small molecules
- Mechanism of Action Activin receptor antagonists; Bone morphogenetic protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Fracture; Multiple myeloma; Osteoarthritis; Osteoporosis
Most Recent Events
- 31 Jul 2018 TiGenix has been acquired by Takeda
- 28 Feb 2018 No recent reports of development identified for preclinical development in Fracture in Belgium
- 28 Feb 2018 No recent reports of development identified for preclinical development in Multiple-myeloma in Belgium